CNMD - CONMED Corporation
NYSE
->
Healthcare
->
Medical Devices
Largo,
United States
Type: Equity
CNMD price evolution
CNMD
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $28.87 | $33.85 | $24.3 | $30.5 |
| Short term investments | ||||
| Net receivables | $239.22 | $241.46 | $242.28 | $230.2 |
| Inventory | $322.36 | $322.3 | $318.32 | $325.82 |
| Total current assets | $623.83 | $635.72 | $615.65 | $625.65 |
| Long term investments | ||||
| Property, plant & equipment | $117.09 | $117.95 | $120.72 | $120.44 |
| Goodwill & intangible assets | $1439.44 | $1447.59 | $1456.33 | $1472.5 |
| Total noncurrent assets | $1661.78 | $1673.53 | $1684.37 | $1700.03 |
| Total investments | ||||
| Total assets | $2285.62 | $2309.26 | $2300.02 | $2325.68 |
| Current liabilities | ||||
| Accounts payable | $101.29 | $101.64 | $88.22 | $81.87 |
| Deferred revenue | ||||
| Short long term debt | $0.72 | $0.69 | $0.71 | $70.63 |
| Total current liabilities | $266.41 | $291.4 | $310.73 | $376.32 |
| Long term debt | $965.17 | $990.11 | $973.14 | $942.17 |
| Total noncurrent liabilities | $1137.37 | $1163.19 | $1155.07 | $1153.15 |
| Total debt | $965.89 | $990.8 | $973.85 | $1012.79 |
| Total liabilities | $1403.78 | $1454.59 | $1465.8 | $1529.47 |
| Shareholders' equity | ||||
| Retained earnings | $489.89 | $466.08 | $452.53 | $425.61 |
| Other shareholder equity | -$54.43 | -$49.8 | -$50.17 | -$53.96 |
| Total shareholder equity | $881.83 | $854.66 | $834.22 | $796.21 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $24.3 | $28.94 | $20.85 | $27.36 |
| Short term investments | ||||
| Net receivables | $242.28 | $191.34 | $183.88 | $177.15 |
| Inventory | $318.32 | $332.32 | $231.64 | $194.87 |
| Total current assets | $615.65 | $581.23 | $460.12 | $416.65 |
| Long term investments | ||||
| Property, plant & equipment | $120.72 | $133.32 | $108.86 | $133.07 |
| Goodwill & intangible assets | $1456.33 | $1497.23 | $1088.58 | $1119.98 |
| Total noncurrent assets | $1684.37 | $1716.37 | $1305.89 | $1335.02 |
| Total investments | ||||
| Total assets | $2300.02 | $2297.59 | $1766.02 | $1751.67 |
| Current liabilities | ||||
| Accounts payable | $88.22 | $73.39 | $58.2 | $53.31 |
| Deferred revenue | ||||
| Short long term debt | $0.71 | $69.75 | $12.25 | $18.22 |
| Total current liabilities | $310.73 | $296.55 | $196.65 | $190.2 |
| Long term debt | $973.14 | $985.08 | $672.41 | $734.83 |
| Total noncurrent liabilities | $1155.07 | $1255.49 | $783.94 | $852.43 |
| Total debt | $973.85 | $1054.82 | $684.66 | $753.64 |
| Total liabilities | $1465.8 | $1552.05 | $980.58 | $1042.63 |
| Shareholders' equity | ||||
| Retained earnings | $452.53 | $412.63 | $496.61 | $457.42 |
| Other shareholder equity | -$50.17 | -$57.86 | -$54.2 | -$63.68 |
| Total shareholder equity | $834.22 | $745.54 | $785.43 | $709.04 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $332.1 | $312.27 | $327.05 | $304.58 |
| Cost of revenue | $148.37 | $140.31 | $136.52 | |
| Gross Profit | $183.73 | $171.97 | $184.33 | $168.06 |
| Operating activities | ||||
| Research & development | $14.1 | $13.59 | $12.46 | |
| Selling, general & administrative | $122.52 | $123.36 | $125.3 | |
| Total operating expenses | $136.62 | $136.95 | $131.99 | $137.76 |
| Operating income | $47.11 | $35.01 | $30.3 | |
| Income from continuing operations | ||||
| EBIT | $47.11 | $35.01 | $30.3 | |
| Income tax expense | $7.54 | $5.71 | $7.61 | $4.44 |
| Interest expense | $9.59 | $9.59 | -$9.51 | $10.02 |
| Net income | ||||
| Net income | $29.98 | $19.71 | $33.07 | $15.84 |
| Income (for common shares) | $29.98 | $19.71 | $15.84 | |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1244.74 | $1045.47 | $862.46 | |
| Cost of revenue | $474.23 | $385.5 | ||
| Gross Profit | $686.9 | $571.25 | $476.95 | |
| Operating activities | ||||
| Research & development | $47.15 | $40.47 | ||
| Selling, general & administrative | $454.04 | $366.1 | ||
| Total operating expenses | $551.21 | $613.2 | $792.08 | |
| Operating income | -$41.96 | $70.38 | ||
| Income from continuing operations | ||||
| EBIT | -$41.96 | $70.38 | ||
| Income tax expense | $16.37 | $9.72 | -$7.91 | |
| Interest expense | -$39.77 | $28.91 | -$44.05 | |
| Net income | ||||
| Net income | $64.46 | -$80.58 | $9.52 | |
| Income (for common shares) | -$80.58 | $9.52 | ||
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | $29.98 | $19.71 | $33.07 | $15.84 |
| Operating activities | ||||
| Depreciation | $4.17 | $4.05 | $4.05 | $3.93 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.97 | $6.24 | $5.92 | $6.19 |
| Total cash flows from operations | $43.31 | $29.12 | $56.4 | $46.13 |
| Investing activities | ||||
| Capital expenditures | -$3.59 | -$2.04 | -$4.86 | -$5.39 |
| Investments | ||||
| Total cash flows from investing | -$3.59 | -$2.04 | -$4.86 | -$5.39 |
| Financing activities | ||||
| Dividends paid | -$6.16 | -$6.15 | -$6.15 | -$6.14 |
| Sale and purchase of stock | ||||
| Net borrowings | -$26 | $16 | -$40 | -$32 |
| Total cash flows from financing | -$44.09 | -$17.01 | -$58.77 | -$37.23 |
| Effect of exchange rate | -$0.62 | -$0.51 | $1.02 | -$0.85 |
| Change in cash and equivalents | -$4.99 | $9.56 | -$6.21 | $2.65 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | $64.46 | -$80.58 | $62.54 | $9.52 |
| Operating activities | ||||
| Depreciation | $16.2 | $16.05 | $16.49 | $67.92 |
| Business acquisitions & disposals | -$227.74 | |||
| Stock-based compensation | $24.26 | $21.73 | $16.34 | |
| Total cash flows from operations | $125.35 | $33.37 | $111.77 | $64.53 |
| Investing activities | ||||
| Capital expenditures | -$19.03 | -$21.79 | -$14.87 | -$13.01 |
| Investments | ||||
| Total cash flows from investing | -$20.03 | -$249.53 | -$14.87 | -$13.64 |
| Financing activities | ||||
| Dividends paid | -$24.5 | -$23.96 | -$23.26 | -$22.82 |
| Sale and purchase of stock | $72 | |||
| Net borrowings | -$88 | $260.65 | -$81.24 | -$26.25 |
| Total cash flows from financing | -$110.43 | $225 | -$101.55 | -$52.06 |
| Effect of exchange rate | $0.47 | -$0.74 | -$1.86 | $2.67 |
| Change in cash and equivalents | -$4.65 | $8.1 | -$6.51 | $1.5 |
News
Fundamentals
| Market cap | $2.29B |
|---|---|
| Enterprise value | $3.22B |
| Shares outstanding | 30.82M |
| Revenue | $1.28B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $98.59M |
| Revenue Q/Q | 4.55% |
| Revenue Y/Y | 12.02% |
| P/E ratio | 23.19 |
|---|---|
| EV/Sales | 2.53 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.79 |
| P/B ratio | 2.44 |
| Book/Share | 30.38 |
| Cash/Share | 0.94 |
| EPS | $3.20 |
|---|---|
| ROA | 4.28% |
| ROE | 11.71% |
| Debt/Equity | 1.76 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.34 |
| Quick ratio | 1.13 |